Last reviewed · How we verify
NCT00091871
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
trial in Eosinophilia in 50 participants. Currently enrolling.
Quick facts
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 8 June 2005 |
| Sites | 1 location across United States |
Conditions studied
- Eosinophilia — all drugs for Eosinophilia →
- Hypereosinophilic Syndrome — all drugs for Hypereosinophilic Syndrome →
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Who can join
Adults 1 to 100, any sex, with Eosinophilia or Hypereosinophilic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophilic syndrome (HES). Some individuals have a hereditary form of HES known as familial eosinophilia (FE). More research on the causation and mechanisms of HES is needed in order to design more effective and less toxic therapies. This study will investigate FE and its genetic causes, damage mechanisms, and disease markers (such as blood test abnormalities). It will enroll approximately 50 individuals (both adults and children) from a previously studied family with FE. This is a long-term study of indefinite duration. Participants will undergo yearly clinical examinations including medical history, physical examination, bloodwork, EKG, echocardiogram, and pulmonary function tests, with additional or more frequent examinations and tests as required. In addition, participants will donate blood and tissue for research purposes. Both adult and child participants will donate blood. At the initial evaluation, adult participants will donate bone marrow. During the study, some adult participants will also undergo a limited number of leukaopheresis sessions, in which blood is donated from one arm, the blood is separated into red blood cells and other components, and the red blood cells are returned into the donor's other arm.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The multidisciplinary approach to eosinophilia.
Thomsen GN, Christoffersen MN, Lindegaard HM, Davidsen JR, et al · · 2023 · cited 21× · PMID 37274287 · DOI 10.3389/fonc.2023.1193730 -
Dysregulation of interleukin 5 expression in familial eosinophilia.
Prakash Babu S, Chen YK, Bonne-Annee S, Yang J, et al · · 2017 · cited 15× · PMID 28226398 · DOI 10.1111/all.13146
Verify or expand the search:
- PubMed search for NCT00091871
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Eosinophilia
Currently open trials in the same condition.
- NCT06265870 — Specific Versus Empirical Anthelminthic Treatment in Eosinophilia · NA · recruiting
- NCT05942222 — A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis Wit · Phase 4 · active not recruiting
- NCT03801434 — Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders · Phase 2 · recruiting
- NCT00001406 — Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia · recruiting
Other National Institute of Allergy and Infectious Diseases (NIAID) trials
Trials by the same sponsor.
- NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · not yet recruiting
- NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
- NCT06987318 — A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) · Phase 1 · not yet recruiting
- NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of · Phase 1, PHASE2 · not yet recruiting
- NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00091871 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID)
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00091871.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing